Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 5/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | ESR1 | P03372 | 1/20 | 0.40 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.40 |
| ▸ | FGFR2 | P21802 | 3/20 | 0.40 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14729742 | 1.00 | TDP1 (0.44) | TDP1MAPTNPC1LMNARAB9A | |
| SCHEMBL12320829 | 0.87 | TDP1 (0.49) | TDP1MAPTNPC1LMNARAB9A | |
| SCHEMBL14729789 | 0.84 | ALDH1A1 (0.41) | TDP1MAPTNPC1LMNARAB9A | |
| SCHEMBL14716600 | 0.84 | ALDH1A1 (0.41) | TDP1MAPTNPC1LMNARAB9A | |
| SCHEMBL14716735 | 0.83 | FGFR1 (0.53) | TDP1MAPTNPC1LMNARAB9A | |
| SCHEMBL14716516 | 0.80 | XDH (0.47) | TDP1MAPTNPC1LMNARAB9A | |
| SCHEMBL12320449 | 0.80 | XDH (0.47) | TDP1MAPTNPC1LMNARAB9A | |
| SCHEMBL14729780 | 0.77 | MAPT (0.40) | TDP1MAPTNPC1LMNARAB9A | |
| SCHEMBL14716707 | 0.74 | TDP1 (0.46) | TDP1MAPTNPC1LMNARAB9A | |
| SCHEMBL18409069 | 0.70 | NPC1 (0.67) | TDP1MAPTNPC1LMNARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9458515-B2 | RNA including nucleoside compound, method for regulating amount of protein produced from the RNA, and nucleoside compound | RIKEN (JP) | 2016-10-04 | — | — | US | disclosed |
| US-20130052710-A1 | RNA INCLUDING NUCLEOSIDE COMPOUND, METHOD FOR REGULATING AMOUNT OF PROTEIN PRODUCED FROM THE RNA, AND NUCLEOSIDE COMPOUND | RIKEN (JP) | 2013-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130052710-A1 | RNA INCLUDING NUCLEOSIDE COMPOUND, METHOD FOR REGULATING AMOUNT OF PROTEIN PRODUCED FROM THE RNA, AND NUCLEOSIDE COMPOUND | RNMT, NSUN2, RNGTT | TDP1 1242/4885MAPT 4281/4885NPC1 1129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.